Brad Pyatt relinquishes the MusclePharm Corp. helm as the firm rebounds from management missteps that led to fines for securities violations and to help from investors including the firm's current executive chairman, Ryan Drexler, who will be interim president and CEO. The Denver firm on March 16 said Pyatt, who launched the company in 2008, also will step down from the board. Drexler in June acquired a 10.9% stake in MusclePharm, became executive chairman in August and later gained the right to appoint two members to the board after making a $6m loan for the firm’s general expenses and guaranteeing $6.2m in bank loans ([A#05151214009]).
Twinlab Consolidated Holdings Inc. appoints Naomi Whittel, previously head of a firm Twinlab acquired in late 2015, as president and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?